Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

2.420 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Expert Ratings For Caribou Biosciences
 
Via Benzinga
Attention Biotech Investors - Stocks To Watch
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,... 
Via Benzinga
3 Underappreciated Stocks That Could 10x in 10 Years
10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line. 
Via InvestorPlace
CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024
CRBU stock results show that Caribou Biosciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Caribou Biosciences, Inc.
Via GlobeNewswire
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. 
Via Benzinga
Topics Stocks
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
From Caribou Biosciences, Inc.
Via GlobeNewswire
Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the "Greed" zone on Tuesday. 
Via Benzinga
Topics Economy Stocks
Gold Down Over 1%; ClearOne Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also... 
Via Benzinga
Topics Stocks
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Caribou Biosciences Stock Is Crashing Today
Investors didn't like the clinical-stage biotech's Q4 update for one key reason. 
Via The Motley Fool
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold
Buy this stock if you're daring, but avoid it for now if you aren't. 
Via The Motley Fool
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
It's less scary to take on risky investments when the market is rising. 
Via The Motley Fool
3 Biotech Stocks You Can Buy and Hold for the Next Decade
These companies are still in the early innings of their growth potential. 
Via The Motley Fool
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
From Caribou Biosciences, Inc.
Via GlobeNewswire
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.